Maintaining a high profile presence at all the major international forums devoted to cancer research has allowed the CNIO to attract extremely talented and qualified people to its ranks, explore new sources of financing and discuss joint initiatives with academic and industry partners. To that end, its Department of International Affairs has been tasked with making sure the CNIO plays a leading role in these meetings and, in broad terms, continues to be regarded as a major player among cancer research institutions.
The priorities of the Department are:
- To undertake strategic partnerships and participate fully in networked initiatives with other prestigious centers dedicated to cancer research.
- To identify and map out long term projects with the support and involvement of national and international foundations.
- To play an active role in national and international forums dealing with academic issues, policy matters relating to science and innovation, and to help establish priorities for major research initiatives.
- To raise the institutional profile and attract the best scientific talent to the CNIO.
- To formalize strategic alliances with global companies as a stimulus to research.
The CNIO is an academic institution affiliated with the Milner Therapeutics Alliance, an organization based in Cambridge (United Kingdom) dedicated to transforming the findings of basic science into tangible benefits, such as the development of new drugs. The Alliance brings together 17 universities and other research centres, 55 leading industries in the biomedical sector, and two capital investment firms.
Another productive and consolidated partnership is our collaboration with the prominent, Israel-based Weizmann Institute of Science and the Ramon Areces Foundation to encourage scientific interaction between our research teams and those at the Moross Integrated Cancer Centre (MICC) at the Weizmann. In 2017 this tripartite alliance held their first joint symposium in Madrid and has agreed to launch call for joint projects in which researchers from the CNIO and the Weizmann are the lead authors, thereby amplifying the synergies between two of the world’s most forward-looking institutions in cancer discovery.